Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

Exclusion Criteria

• •1. Women during pregnancy or lactation, or fertile women unwilling to take contraceptive measures.
• •2. QTc elongation with clinical significance ( male˃ 450ms, female˃ 470ms), ventricular tachycardia, atrial fibrillation, cardiac conducting blockage, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease that requires treatment.
• •3. Cardiac B ultrasound show end-diastolic pericardial dark zone≥ 10cm
• •4. Patients who have received organ transplantation.
• •5. Patients received symptomatic treatment for bone marrow toxicity within 7 days prior to enrollment.
• •6. Patients with active hemorrhage.
• •7. Patients with or with history of thrombosis, embolism, cerebral hemorrhage, or cerebral infarction.
• •8. Patients with active infection, or with continuous fever within 14 days prior to enrollment.
• •9. Had major organ surgery within 6 weeks prior to enrollment.
• •10. Abnormal blood routine test results within 14 days prior to enrollment (Hb˂80g/L，ANC˂1.0×109/L，PLT˂75×109/L； Impaired liver function ( Total bilirubin ˃ 1.5 times of normal maximum, ALT/AST˃ 2.5 times of normal maximum, for patients with infiltrative liver disease ALT/AST ˃ 5 times of normal maximum), impaired renal function (serum creatinin˃ 1.5 times of normal maximum).
• •11. Patients with history of Chidamide treatment and had disease progression within 6 months afterward;
• •12. Patients that received large dose of steroids (˃10mg/d dexamethasone or other steroids of the equivalent dosage) within 4 weeks prior to enrollment;
• •13. Patients with hemophagocytic syndrome;
• •14. Patients with central nerve system diseases or history of central nerve system diseases;
• •15. Patients with mental disorders or those do not have the ability to consent;
• •16. Patients that had been enrolled in other clinical trials within 3 months prior to enrollment;
• •17. Patients with drug abuse, long term alcoholism that may impact the results of the trial.
• •18. Non-appropriate patients for the trial according to the judgment of the investigators.